Urology
 |
|
12 october 2019 00:00:49 |
| Re: Thomas Loubersac, Molière Nguile-Makao, Frédéric Pouliot, Vincent Fradet, Paul Toren. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2019.01.009Re: thomas Loubersac, Molière Nguile-Makao, Frédéric Pouliot, Vincent Fradet, Paul Toren. Neutrophil-to-lymphocyte ratio as a predictive marker of response to abiraterone acetate: a retrospective analysis (European Urology Oncology) |
|
Tweet We read with great interest the article by Loubersac et al [1]. The authors conclude that for men with asymptomatic metastatic castration-resistant prostate cancer, the baseline neutrophil-to-lymphocyte ratio (NLR) might be able to predict response to abiraterone, but changes in the NLR while on treatment are not sufficient for guiding treatment. We agree that the NLR might be a good biomarker and the results in the present study are concordant with a recent report by Yasui et al [2]. However, there are some points to be discussed. |
| 227 viewsCategory: Oncology, Urology |
 What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review (European Urology Oncology)Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy (European Urology Oncology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page